Loading...
XBRU
SEQUA
Market cap68mUSD
Sep 19, Last price  
0.97EUR
1D
-1.73%
1Q
-15.26%
IPO
-87.05%
Name

Sequana Medical NV

Chart & Performance

D1W1MN
P/E
—
P/S
550.48
EPS
—
Div Yield, %
—
Shrs. gr., 5y
24.38%
Rev. gr., 5y
-35.78%
Revenues
106k
-85.12%
1,684,9181,488,7991,303,9751,029,171970,636963,280370,500922,687712,173106,000
Net income
-45m
L+37.13%
000-13,983,224-14,977,446-19,106,205-23,615,080-30,763,084-32,563,574-44,654,000
CFO
-20m
L-29.74%
000-9,875,346-18,482,352-17,005,228-23,617,366-27,481,845-29,063,346-20,420,000

Profile

Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.
URL
https://www.sequanamedical.com/
IPO date
Feb 11, 2019
Employees
70
Domiciled in
BE
Incorporated in
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
106
-85.12%
712
-22.82%
923
149.04%
Cost of revenue
2,324
12,947
16,839
Unusual Expense (Income)
NOPBT
(2,218)
(12,235)
(15,916)
NOPBT Margin
Operating Taxes
280
466
387
Tax Rate
NOPAT
(2,498)
(12,701)
(16,303)
Net income
(44,654)
37.13%
(32,564)
5.85%
(30,763)
30.27%
Dividends
Dividend yield
Proceeds from repurchase of equity
11,665
15,786
28,420
BB yield
-10.42%
-14.74%
-20.80%
Debt
Debt current
39,753
8,087
4,790
Long-term debt
358
10,166
13,719
Deferred revenue
Other long-term liabilities
754
668
228
Net debt
36,200
15,568
(452)
Cash flow
Cash from operating activities
(20,420)
(29,063)
(27,482)
CAPEX
(95)
(711)
(677)
Cash from investing activities
(100)
(721)
(653)
Cash from financing activities
21,717
13,461
37,324
FCF
3
(7,867)
(17,102)
Balance
Cash
3,807
2,584
18,875
Long term investments
104
100
86
Excess cash
3,906
2,649
18,915
Stockholders' equity
(245,223)
(205,110)
(170,998)
Invested Capital
241,709
203,832
186,665
ROIC
ROCE
63.12%
957.66%
EV
Common stock shares outstanding
36,602
26,774
22,770
Price
3.06
-23.50%
4.00
-33.33%
6.00
-20.63%
Market cap
112,001
4.58%
107,096
-21.61%
136,617
-0.78%
EV
148,201
122,665
137,645
EBITDA
(1,603)
(11,574)
(15,605)
EV/EBITDA
Interest
26,363
4,288
880
Interest/NOPBT